4.7 Article

A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2

Journal

EBIOMEDICINE
Volume 74, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ebiom.2021.103729

Keywords

SARS-CoV-2; Neturalising antibodies; Lateral flow assay; Point of care test

Funding

  1. Australian Governments
  2. Department of Health and Human Services (DHHS) of the Victorian State Government
  3. Australian Research Council (ARC) [CE140100011, CE140100036]
  4. Medical Research Future Fund (MRFF) Awards [2005544, 2002073, 2002132]
  5. NHMRC [1194036, 1116530, 1173871, 1137285, 1177174, 1174555, 1117766, 1136322]
  6. A2 Milk Company
  7. Jack Ma Foundation
  8. Australian Government Department of Health
  9. National Health and Medical Research Council of Australia (NHMRC) [1116530, 1113293, 2002317]
  10. National Health and Medical Research Council of Australia [1116530, 1174555, 1177174, 1194036, 1117766, 1137285, 1136322] Funding Source: NHMRC

Ask authors/readers for more resources

This study developed a lateral flow POC test that can rapidly measure levels of SARS-CoV-2 neutralising antibodies, showing a high correlation with conventional neutralisation and applicability with animal samples. The test can also be used to assess protection against new variants and can be conducted using fingerprick whole blood samples.
Background: As vaccines against SARS-CoV-2 are now being rolled out, a better understanding of immunity to the virus, whether from infection, or passive or active immunisation, and the durability of this protection is required. This will benefit from the ability to measure antibody-based protection to SARS-CoV-2, ideally with rapid turnaround and without the need for laboratory-based testing. Methods: We have developed a lateral flow POC test that can measure levels of RBD-ACE2 neutralising antibody (NAb) from whole blood, with a result that can be determined by eye or quantitatively on a small instrument. We compared our lateral flow test with the gold-standard microneutralisation assay, using samples from convalescent and vaccinated donors, as well as immunised macaques. Findings: We show a high correlation between our lateral flow test with conventional neutralisation and that this test is applicable with animal samples. We also show that this assay is readily adaptable to test for protection to newly emerging SARS-CoV-2 variants, including the beta variant which revealed a marked reduction in NAb activity. Lastly, using a cohort of vaccinated humans, we demonstrate that our whole-blood test correlates closely with microneutralisation assay data (specificity 100% and sensitivity 96% at a microneutralisation cutoff of 1:40) and that fingerprick whole blood samples are sufficient for this test. Interpretation: Taken together, the COVID-19 NAb-test (TM) device described here provides a rapid readout of NAb based protection to SARS-CoV-2 at the point of care. (C) 2021 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available